C4X Discovery Signs Licensing Deal with AstraZeneca Worth up to $402 Million
November 28 2022 - 03:04AM
Dow Jones News
By Joe Hoppe
C4X Discovery Holdings PLC said Monday that it has signed a
worldwide licensing deal with AstraZeneca PLC worth up to $402
million for the development and commercialization of its NRF2
Activator program.
The drug discovery company said it was eligible to receive
pre-clinical milestone payments worth up to $16 million ahead of
the first clinical trial, including $2 million upfront. The deal
also includes payments for development and commercial milestones,
and tiered mid-single digit royalties.
The company said AstraZeneca will develop and commercialize an
oral therapy for the treatment of inflammatory and respiratory
diseases, with a lead focus on chronic obstructive pulmonary
disease.
Write to Joe Hoppe at joseph.hoppe@wsj.com
(END) Dow Jones Newswires
November 28, 2022 02:49 ET (07:49 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Feb 2023 to Mar 2023
AstraZeneca (NASDAQ:AZN)
Historical Stock Chart
From Mar 2022 to Mar 2023
